Therapy of rheumatoid arthritis by S1P receptor antagonisit and IL-2/IL-2 antibody immune complex

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09538
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Collagenous pathology/Allergology
• Research Institution: Hyogo Medical University
• Principal Investigator: SANO HAJIME 兵庫医科大学, 医学部, 教授 (00196304)
• Co-Investigator(Kenkyū-buntansha): 岩崎 剛 兵庫医療大学, 薬学部, 教授 (10151721)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 関節リウマチ / IL-2 免疫複合体 / 制御性T細胞 / IL-10 / Th1 / Th17 / CIAマウス

Outline of Final Research Achievements

To determine the effect of IL-2IC on established CIA, IL-2IC was administered for 3days from day 21 to day 23 after first immunization of CIA. To define effect of IL-2 IC on early stages of diseaseas induction we administratedIL-2IC from day 0-2 after immunization. We observed a significant decrease in both the induction the incidence and severity of arthritis in CIA mice.
Injection of IL-2IC effectively elicited more than 2-fold expansion of CD4+CD25+Foxp3+ Tregs in peripheral blood cells than control　mice. Th1 and Th17 cellls infiltrations in the synovium were significantly inhibited by IL-2IC treatment. Intracellular cytokine staining revealed that IL-10 production by CD4+ cells in IL-2IC treated spleen increased four folds than in controls, and IFN-γproducing helper T cells (Th1) and Th17 producing helper T cells (Th17) were significantly decreased. Thease observations induces thatIL-2IC not only induce Tregs, but also augments Treg function by enhancing IL-10 production .

Free Research Field

リウマチ学